

Article

Toxicological Analysis of Hepatocytes Using FLIM Technique: In Vitro versus Ex Vivo Models

Svetlana Rodimova ^{1,2,*} , Vadim Elagin ¹ , Maria Karabut ¹, Irina Koryakina ³, Alexander Timin ^{4,5}, Vladimir Zagainov ^{1,6}, Mikhail Zyuzin ³ , Elena Zagaynova ^{1,2} and Daria Kuznetsova ^{1,2}

- ¹ Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603000 Nizhny Novgorod, Russia; elagin.vadim@gmail.com (V.E.); maria.karabut@gmail.com (M.K.); zagainov@gmail.com (V.Z.); ezagaynova@gmail.com (E.Z.); daria.s.kuznetsova@gmail.com (D.K.)
 - ² Department of Biophysics, N.I. Lobachevsky Nizhny Novgorod National Research State University, 23 Gagarina Ave., 603022 Nizhny Novgorod, Russia
 - ³ School of Physics and Engineering, ITMO University, 9 Lomonosova St., 191002 St. Petersburg, Russia; irina.koryakina@metalab.ifmo.ru (I.K.); mikhail.zyuzin@metalab.ifmo.ru (M.Z.)
 - ⁴ Research School of Chemical and Biomedical Engineering, National Research Tomsk Polytechnic University, 30 Lenin Ave., 634034 Tomsk, Russia; a_timin@mail.ru
 - ⁵ Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, 29 Polytechnicheskaya St., 194064 St. Petersburg, Russia
 - ⁶ The Volga District Medical Centre of Federal Medical and Biological Agency, 14 Ilinskaya St., 603000 Nizhny Novgorod, Russia
- * Correspondence: srodimova123@gmail.com



Citation: Rodimova, S.; Elagin, V.; Karabut, M.; Koryakina, I.; Timin, A.; Zagainov, V.; Zyuzin, M.; Zagaynova, E.; Kuznetsova, D. Toxicological Analysis of Hepatocytes Using FLIM Technique: In Vitro versus Ex Vivo Models. *Cells* **2021**, *10*, 2894. <https://doi.org/10.3390/cells10112894>

Academic Editor: Ali Canbay

Received: 31 August 2021

Accepted: 23 October 2021

Published: 26 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The search for new criteria indicating acute or chronic pathological processes resulting from exposure to toxic agents, testing of drugs for potential hepatotoxicity, and fundamental study of the mechanisms of hepatotoxicity at a molecular level still represents a challenging issue that requires the selection of adequate research models and tools. Microfluidic chips (MFCs) offer a promising in vitro model for express analysis and are easy to implement. However, to obtain comprehensive information, more complex models are needed. A fundamentally new label-free approach for studying liver pathology is fluorescence-lifetime imaging microscopy (FLIM). We obtained FLIM data on both the free and bound forms of NAD(P)H, which is associated with different metabolic pathways. In clinical cases, liver pathology resulting from overdoses is most often as a result of acetaminophen (APAP) or alcohol (ethanol). Therefore, we have studied and compared the metabolic state of hepatocytes in various experimental models of APAP and ethanol hepatotoxicity. We have determined the potential diagnostic criteria including the pathologically altered metabolism of the hepatocytes in the early stages of toxic damage, including pronounced changes in the contribution from the bound form of NAD(P)H. In contrast to the MFCs, the changes in the metabolic state of hepatocytes in the ex vivo models are, to a greater extent, associated with compensatory processes. Thus, MFCs in combination with FLIM can be applied as an effective tool set for the express modeling and diagnosis of hepatotoxicity in clinics.

Keywords: FLIM; microfluidic chip; hepatocyte; liver pathology; metabolism

1. Introduction

There are a number of hepatotoxic agents that cause either acute or chronic damage [1]. Among them, ethanol and acetaminophen (APAP) can be considered as two of the most common hepatotoxins. For instance, APAP is a safe analgesic at therapeutic levels. However, an overdose of APAP can cause serious liver injury and even lead to liver dysfunction [2]. High doses of ethanol through alcohol abuse can cause the development of alcoholic liver disease, which can further promote fibrosis, cirrhosis or hepatocellular carcinoma [3].

The metabolism of ethanol and APAP alters the metabolic state of hepatocytes. Importantly, the degree of hepatic toxicity correlates with both the activity of the catalyzing enzyme systems and the availability of glutathione (GSH) in the hepatocytes. An absence of GSH leads to covalent binding of the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) to form NAPQI-protein adducts [4,5].

The mechanisms of hepatotoxicity of APAP and ethanol are illustrated in Figure 1 ((a) is APAP and (b) is ethanol).




Figure 1. Schematic diagrams of the hepatotoxicity mechanisms. (a) APAP and (b) ethanol. The percentage distribution of the APAP metabolic pathways is represented by averaged values, and these are in agreement with the published works [6,7].

APAP: Therapeutic doses of APAP result in the generation of small quantities of NAPQI that are easily detoxified by GSH. Excessive doses of APAP lead to the shunting of more APAP into the cytochrome P450 (CYP) system. Increased metabolism of APAP by CYP, in turn, increases the amount of NAPQI [8,9]. Further, excessive accumulation of NAPQI critically decreases the limited resource of GSH, thereby reducing the detoxifying capacity of the liver. In the absence of free GSH, the excess of NAPQI interacts with the cysteine groups of macromolecules within the hepatocytes, forming NAPQI-protein adducts, leading to mitochondrial dysfunction and the loss of cellular ATP. GSH depletion further contributes to cellular oxidant stress [10–12]. Therefore, as final outcomes of the APAP overdose, an alteration in calcium homeostasis, mitochondrial dysfunction with ATP depletion, DNA damage, and intracellular protein modification can occur [13–15].

Ethanol: The oxidative pathways of alcohol metabolism involve three enzymes: alcohol dehydrogenase (ADH) in the cytosol; cytochrome P450 (CYP) in the microsomes; and catalase in the peroxisomes [16]. ADH converts alcohol to acetaldehyde and other metabolites. In this reaction, NAD⁺ is reduced by two electrons to NADH, generating a highly reduced environment in the hepatocyte cytosol. The increased NADH/NAD⁺ ratio favors hepatic triglyceride accumulation. CYP enzymes (in particular, the microsomal ethanol oxidizing system (MEOS)) that are located mainly in the microsomes and endoplasmic reticulum also contribute to the metabolism of alcohol into acetaldehyde. Acetaldehyde is a highly reactive and toxic byproduct that may contribute to tissue damage because it forms a variety of protein and DNA adducts that promote GSH depletion, lipid peroxidation, and mitochondrial damage [17]. It also contributes to changes in the redox state of the cell and the formation of reactive oxygen species (ROS), [18] which in turn lead to intramitochondrial oxidative stress [19–21].

In this regard, decreasing oxidative stress in the hepatocytes than can be induced by the administration of GSH, N-acetylcysteine, and Cyclophilin D can be considered as a common strategy for the treatment of liver diseases caused by APAP or ethanol [15,20,22].

Thus, evaluation of the metabolic state of hepatocytes is an urgent task both for understanding the fundamental mechanisms of hepatotoxicity and for finding new therapeutic agents for liver treatment. Different *in vitro*, *ex vivo* and *in vivo* experimental models can be used for monitoring the level of hepatotoxicity induced by ethanol or APAP.

In general, while rats are commonly used as an animal model for the investigation of ethanol hepatotoxicity, mice are used to study the mechanisms of APAP-induced hepatocyte death. The reason mice were chosen as a suitable model for revealing the influence of APAP on hepatocytes is that rats are resistant to APAP damage. Furthermore, mice are widely used to test APAP hepatotoxicity, since the induced toxic damage in this case is similar to that in humans [22,23]. Although *in vivo* models reflect the real situation, one important limitation of animal models is that the results can be hard to interpret due to the systemic intoxication induced by the toxic agent. Moreover, in these models, stimulation of chronic damage by a number of toxins (e.g., ethanol) is long-term and can take from 4 to 12 weeks. In addition, the use of animal models presents a wide range of ethical concerns [24–26].

Employing *ex vivo* analysis of tissue slices enables the preservation of the complex multicellular architecture supporting the native components of the intercellular matrix and cellular interactions. However, if it is necessary to analyze metabolic changes directly in the hepatocytes, then the slice model is inferior, because interpreting it is complicated by the influence of the surrounding non-parenchymal cells [27,28].

In vitro models can be more appropriate for simple and fast analysis of hepatotoxicity [29]. In this context, microfluidic technology can help to establish *in vitro* conditions similar to *ex vivo*/*in vivo* environments. Indeed, the microfluidic method opens up the possibility of mimicking the functions of organs *in vitro*. For instance, with microfluidic chips (MFCs), adjustment of the environmental conditions is possible according to the type of cell. Thus, microfluidics has emerged as a suitable tool for cell manipulation and cell study, as the culture of cells in such flow conditions facilitates the supply of nutrients or other compounds (drugs, toxins) required to study the cellular response [30]. As pointed out in a published study [31], microfluidics can maintain the hepatocytes' synthetic and metabolic functions. In the same work, microfluidic chips proved to be more sensitive to drug-mediated hepatotoxicity than other methods for most of the drugs tested. Furthermore, *in vitro* toxicity data have been shown to be positively correlated to *in vivo* toxicity data. Another successful example of cell lines or primary cells cultured in MFCs is shown in Ref [32], where MFCs were used for the testing of single or multidrug combination chemotherapy at defined doses.

Here, we have systematically studied hepatotoxicity in different research models, including animal models (mice for APAP analysis, and rats for ethanol analysis), precision-cut slices, and an *in vitro* model using MFCs. All the tested models were compared to each other.

A number of methods are used to analyze the metabolic changes in liver cells caused by toxic damage. In particular, Western blots or enzyme-linked immunosorbent assays provide information about the content of various low molecular weight compounds, as well as specific proteins in the samples [33]. However, these methods do not allow the analysis of freshly prepared samples or living cells, and require tissue destruction and preliminary preparation of the material. Genomic analysis methods have the same drawbacks as they cannot allow monitoring of processes occurring in living cells and do not provide cellular resolution [34]. In addition, although it is possible to analyze blood serum metabolites [35], this method provides only indirect information and is not specific enough. Unlike the above-mentioned methods, fluorescence-lifetime imaging microscopy (FLIM) is label-free, minimally invasive and allows the analysis of fresh tissue samples and living cells [36–41]. Currently, very few works have been performed based on analyses of the metabolic state of hepatocytes with toxic damage [42,43]. Furthermore, until now, no comprehensive FLIM analysis has been carried out on the various models, and especially on the MFC model.

A wide range of fluorescence techniques have found broad application in the microscopy of live specimens, since they are extremely sensitive and can be used to study biochemical interactions at the molecular level [44]. However, fluorescence is characterized not only by the spatial distribution of fluorescence intensity and the fluorescence spectrum, but also by the fluorescence lifetime, i.e., the time a fluorescent molecule spends in an excited state before emitting a photon as it decays back to its ground state. The fluorescence lifetime depends on the type of molecule, its conformation, and the way the molecule interacts with its environment [44,45].

Since the metabolic coenzyme NAD(P)H is autofluorescent, it can be monitored nondestructively and without exogenous labels, using optical techniques [46–48]. Lakowicz et al. proposed the FLIM technique for distinguishing the free and protein-bound states of the NADH cofactor [49]. Taking this into account, the FLIM approach enables analysis of the metabolic state of various cell types, based on such fluorescence lifetime data and the contributions of the free and bound forms of NAD(P)H to cell metabolism [50–54]. The fluorescence lifetime has both short and long lifetime components that reflect whether the NAD(P)H is in the free or protein-bound state, respectively [46], as it is sensitive to the fluorophore's microenvironment, thereby providing a method for distinguishing the free and protein-bound components (and their relative contributions).

Cellular energy metabolism is a complex of biochemical pathways that are associated with the synthesis of ATP, so is a sensitive marker of the cellular state and viability. In particular, energy metabolism undergoes changes through the influence of different agents or because of cell damage. Generally, there are two biochemical pathways in a cell responsible for all ATP synthesis. Under normal conditions, most of the ATP in liver cells is produced by the chain of reactions known as the mitochondrial OXPHOS system. It is the bound form of NADH that is involved in this process [55]. In the OXPHOS, NADH acts as the primary donor of protons and electrons for the electron transport chain of the mitochondria. As a result of such NADH oxidation, a proton gradient (electrochemical potential) is formed [56]. This electrochemical potential gradient is required for the production of ATP by ATP-synthetase [57]. The second pathway for ATP synthesis is glycolysis, where a free form of NADH is involved. As a result of this multistage process, two high-energy ATP molecules, two pyruvate molecules, and two water molecules are formed, while two NAD⁺ molecules are reduced, to form two NADH molecules [58,59]. Under normal conditions, the contribution of glycolysis to energy metabolism is insignificant [60].

However, the pathological effects of toxins (in particular, of ethanol and APAP) can disrupt the functions of mitochondria and the respiratory chain. Such alterations can lead to changes in emphasis of the metabolic pathways for ATP synthesis. Thus, such metabolic changes in hepatocytes can be assessed by the changes in the contributions of the two forms of NADH.

The reduced phosphorylated form, NADPH, is involved in the biosynthesis of fatty acids and steroids, in the pentose phosphate pathway, and in antioxidation defense re-

actions (GSH metabolism) [61]. Thus, use of the FLIM method allows information to be obtained about the changes in the intensity of these metabolic processes where the different forms of NAD(P)H are involved.

2. Materials and Methods

2.1. Fabrication of MFCs and Numerical Simulation of Flow in MFCs

The MFCs used in this study consisted of two chambers separated by an array of pillars (an inner chamber and an outer one). The inner chamber contained hydrodynamic traps for the cells. The MFCs were fabricated using a soft lithography method incorporating a silicone elastomer, PDMS. Numerical modeling of the flows in the microchannels of the MFCs was realized with COMSOL Multiphysics 5.6 software. A detailed description of the MFC fabrication procedure and numerical simulation is presented in Supplementary Materials.

2.2. Experimental Setup with MFCs

Primary hepatocytes were isolated from the liver of a laboratory animal (mouse/rat) and introduced into the inner chamber of an MFC. Syringe pumps filled with complete cell culture medium (with or without toxins) were connected to the outer chamber of the MFC. The cell culture medium (with or without toxins) was pumped for 3 h or 24 h at 37 °C, 5% CO₂. The detailed description of the MFC experimental setup is presented in Supplementary Materials.

2.3. Animal Model

Acute toxic damage of liver tissue caused by APAP was induced in 10 male mice (C57BL/6). For this purpose, the mice were treated intraperitoneally with doses of 500 mg/kg APAP dissolved in warm saline [62]. Induction of chronic ethanol damage of liver tissue was carried out using 10 male rats (Wistar). For this purpose, we performed daily oral administration of a 40% ethanol solution at a dosage of 3 mL/100 g. A 10% ethanol solution was also added to the animal drinker [63]. The healthy livers of 5 mice and 5 rats were compared as controls.

For the microscopic examination, the whole organ of each animal was isolated, washed with PBS in order to remove the blood, and cut to obtain tissue samples with a size of 0.5 × 0.5 cm.

2.4. Precision Cut Liver Slices

In this study, we obtained 15 precision cut liver slices for each experimental group. Fresh hepatic tissue was cut into 1.0 × 1.0 × 0.5 cm³ samples. The fixed samples were cut using a stainless steel blade, under buffered conditions with ice-cold PBS. Immediately after cutting, the samples were placed in a 6-well plate with CO₂-conditioned DMEM supplemented with 10% FBS, 4 mM L-glutamine and antibiotic-antimycotic solution. To induce APAP toxic damage, the slices were then transferred to a 10 mM solution of APAP diluted in DMEM medium with 10% FBS, 4 mM L-glutamine, and antibiotic-antimycotic solution. To induce ethanol toxic damage, further slices were placed in a 25 mM solution of ethanol diluted in DMEM medium with 10% FBS, 4 mM L-glutamine, and antibiotic-antimycotic solution. Slices placed in the medium without toxins were used as a control [28,64]. Further cultivation was carried out in the 12-well plates incubated at 37 °C on an orbital shaker (60 rpm) [65]. After 3 h and 24 h of incubation, slices (from both mice and rats) were visualized using a confocal laser scanning microscope (CLSM).

2.5. Multiphoton Microscopy

All the samples were investigated using confocal laser scanning microscopy (CLSM 880) equipped with a Ti:Sapphire femtosecond laser and time-correlated single photon counting (TCSPC). The average laser power used was approximately 10 mW. An oil immersion objective C Plan-Apochromat 40×/1.3) was used to collect the fluorescence signal. From 10 fields of view for each sample, both the NAD(P)H fluorescence intensity

images and the FLIM data were acquired. To visualize the NAD(P)H fluorescence, the sample was excited with a wavelength of 750 nm, and the fluorescence signal was detected in the range of 450–490 nm. The FLIM analysis was performed using SPCImage software (Becker & Hickl GmbH, Berlin, Germany) with a biexponential decay model. The following parameters were analyzed in 20–30 regions of the cytoplasm of the cells in each field of view: t_m (ps), the amplitude-weighted mean lifetime; t_1 (ps), the fluorescence lifetime of the free form of NAD(P)H (the short decay component); t_2 (ps), the fluorescence lifetime of the bound form of NAD(P)H (the long decay component); and the relative contributions of the free, a_1 (%), and the bound, a_2 (%), forms of NAD(P)H. To remove the background signal of the medium in which the hepatocytes were incubated, we used the Threshold option in the SPCImage software. Moreover, the processing was carried out manually, so we could precisely distinguish the areas of cytoplasm in the hepatocytes. A more detailed description of the multiphoton microscopy experiments is presented in Supplementary Materials.

2.6. Histology

Histological studies were carried out following a standard procedure that is comprehensively described in Supplementary Materials. Finally, 10 micrographs per sample were acquired using an optical microscope to proceed with a routine morphological analysis.

3. Results and Discussion

The design of this study is depicted in Figure 2, where the experimental stages of analysis of the hepatocytes' metabolic state are presented for the MFC model, for precision-cut liver slices, and for the ex vivo samples taken from animals. The main concept of the work was to monitor and compare the metabolic state of the hepatocytes after the introduction of APAP or ethanol, using the FLIM method. The animal model included acute APAP-induced injury caused by a single intraperitoneal injection of the toxin, whereas chronic alcohol injury was created by systematic oral administration of ethanol for 12 weeks. Precision-cut slices, obtained by a microtome, were placed in a culture medium supplemented with APAP or ethanol. In the case of the MFCs, isolated hepatocytes were cultured in a chip, where the relevant toxins (APAP and alcohol) were circulated for a predetermined period of time. In the following sections, we discuss each step in more detail.




Figure 2. Road map of the steps implemented to study hepatotoxicity using different models. (Microfluidic chip: upper row, slices: middle row, ex vivo: bottom row).

3.1. MFC Use for Hepatocytes Culture

An MFC was developed to cultivate primary hepatocytes for study of the influence of the toxic effects of APAP and ethanol. The resulting MFC consisted of two chambers: an inner chamber with hydrodynamic traps designed to trap the cells, and an outer chamber (Supplementary Materials, Figure S1). The culture medium was loaded through the outer chamber. To prevent the cells from being removed by the flow of the culture medium, an array of pillars was placed between the outer and inner chambers. Numerical modelling was performed to evaluate the interaction of the culture medium flowing from the outer chamber with the cells in the inner chamber (Supplementary Materials, Figure S2). According to the numerical simulation results obtained, the cells (red dots, $d = 70 \mu\text{m}$) were captured in the hydrodynamic traps and remained there. Moreover, the captured cells interacted with the flow from the outer chamber when the applied flow rate was in the range from $0.008 \mu\text{L/s}$ to $0.02 \mu\text{L/s}$. Microfluidics attracts a great deal of attention due to the low consumption of materials (both cells and the pumped medium) compared to conventional models such as slices and *in vivo* (*ex vivo*) experiments. Furthermore, the use of a microfluidic approach is able to reduce the number of animals used in *in vivo* testing. In addition, the indisputable advantages of using MFCs are the complete isolation of the cells from the external environment and blood stream imitation. The isolation is achieved by placing the material (liver cells) in the sealed chamber of an MFC. Furthermore, microfluidic systems enable automation of the research process, once the initial loading of the cells into the MFC has taken place. Subsequently, processes such as washing, control of flow rates and reagent concentrations can be fully automated and carried out without the intervention of operators, which therefore reduces the opportunity for error.

3.2. Analysis of Metabolic State of Normal Hepatocytes from Mice

At the beginning of the study, the metabolic state of the hepatocytes was evaluated under normal conditions (without adding toxins), using three types of model (*in vitro* using MFCs, precision-cut slices, and *ex vivo*). The hepatocytes were imaged using the FLIM technique to reveal aspects of the fluorescence lifetimes: amplitude-weighted mean lifetime (t_m), the short t_1 (ps) and long t_2 (ps) decay components, and the relative contributions of the free (a_1 , %) and bound (a_2 , %) forms of NAD(P)H in the hepatocytes for all the models represented. The fluorescence lifetimes of the free and bound forms of NAD(P)H (t_1 and t_2 , respectively) for the MFC model were shorter than those in the slice models and *ex vivo* samples, at both 3 h and 24 h of cultivation (Supplementary Materials, Figure S12). In a number of earlier works, increased values of t_1 and t_2 had been shown to be associated with cell hypoxia or cell damage [39,48,66]. It was also reported that a rise in the mean fluorescence lifetime corresponds either to an increase in glycolysis or to a decrease in oxygen tension [67]. High values of t_1 and t_2 may be associated with a reduced level of synthetic activity in cells. In particular, increased t_1 and t_2 can be observed in stem cells during their differentiation [68]. We assume that the reason for the shorter fluorescence lifetimes (t_1 , t_2) in the MFC model is due to a decrease in the metabolic activity of the hepatocytes, since they were isolated from tissue. In addition, a slight decline in cell viability may further account for the decrease in fluorescence lifetimes, since the metabolic activity of cells is indirectly related to their viability [39,48,69].

The metabolic state of the hepatocytes was analyzed in more detail, based on the fluorescence lifetimes and the relative contributions of the free and bound forms of NAD(P)H, because any change in a_1 or a_2 reflects a switching of cellular energy metabolism to glycolysis or OXPHOS [70,71]. Since the a_2 values are associated with OXPHOS, we subsequently used only this parameter to present the data in the figures. In the case of the MFC model, a statistically significant increase in the contribution of the bound form of NAD(P)H (a_2) compared to that at 3 h was observed after 24 h of cultivation (3 h: $25.55\% \pm 2.8$ and 24 h: $29.31\% \pm 5.1$) (Figure 3). In contrast, in the slice model, a slight decline in the contribution of a_2 was recorded at 24 h compared to that at 3 h (3 h: $27.26\% \pm 2.5$ and 24 h: $25.54\% \pm 4.3$)

(Figure 3). In the ex vivo samples, the contribution of the bound form of NAD(P)H was significantly higher, $32.16\% \pm 2.7$ (Figure 3).




Figure 3. Metabolic imaging of control mouse hepatocytes with the MFC, slice and ex vivo models. (a) Combined images of the bright-field and the autofluorescence of NAD(P)H (left row) with pseudocolor-coded fluorescence life-time imaging microscopy (FLIM) images of the NAD(P)H of the hepatocytes (central and right rows), field of view is $213 \times 213 \mu\text{m}$; (b) scatter plots reflecting the distribution of the values of the fluorescence lifetime contributions of the bound form of NAD(P)H. Here, tm (ps) is the amplitude-weighted mean lifetime (tm); a2 (%) is the relative contribution of the bound form of NAD(P)H; scale bar: $50 \mu\text{m}$.

A decrease in the contribution of the NAD(P)H bound form is generally associated with a cellular metabolic shift to a more glycolytic state with a reduced emphasis on OXPHOS. Since OXPHOS is the principal pathway that normal hepatocytes use for obtaining energy, a low a2 value indicates the hepatocytes are suffering damage or hypoxia [72]. Moreover, the lower a2 values found in the MFCs and in the slices compared with the native tissue in the ex vivo samples presumably indicate a reduced OXPHOS level in the hepatocytes in the former due to the disruption of the native tissue structure and partial cell damage inflicted on them during the manipulations. Furthermore, the metabolic switch in hepatocytes to a more glycolytic state is known to be a specific response to their isolation [73].

3.3. Analysis of Hepatotoxicity of APAP

Next, the metabolic state of hepatocytes was examined after their exposure to APAP (10 mM solution of APAP) in the three different models. The metabolic activity of the isolated hepatocytes cultured in MFCs was checked after 3 h, since it had previously been

demonstrated that the most pronounced metabolic changes under the influence of APAP could be detected in the range of 2–6 h post exposure [74,75]. Analysis of the metabolic state of the hepatocytes after APAP administration revealed that the fluorescence lifetimes t_1 and t_2 were much shorter in the MFC model compared to those in the slices and ex vivo samples, as had been shown previously, without the addition of APAP (Supplementary Materials, Figure S12). This indicated a decline in the overall metabolic activity of the hepatocytes damaged after exposure to APAP.

On analyzing the contribution of bound NAD(P)H, a_2 (%), the MFC model showed a reduced contribution of the bound form of NAD(P)H compared to hepatocytes without the addition of APAP (3 h: $17.6\% \pm 2.1$, and 24 h: $20.16\% \pm 6.9$) (Figure 4).




Figure 4. Metabolic imaging of mouse hepatocytes exposed to APAP in the MFC, slice and ex vivo models. (a) Combined images of the bright-field and autofluorescence of NAD(P)H (left row) with pseudocolor-coded FLIM images of the NAD(P)H of the hepatocytes (central and right rows), field of view is $213 \times 213 \mu\text{m}$; (b) scatter plots reflecting the distribution of the values of the fluorescence lifetime contributions of the bound form of NAD(P)H. Here, t_m (ps) is the amplitude-weighted mean lifetime (t_m); a_2 (%) is the relative contribution of the bound form of NAD(P)H; scale bar: $50 \mu\text{m}$.

As shown in our previous work, OXPHOS predominates in normal hepatocytes and, accordingly, the contribution of the bound form of NAD(P)H is high [53]. The drop in the contribution of the bound form of NAD(P)H in isolated hepatocytes is consistent with the known mechanisms of APAP hepatotoxicity. Specifically, APAP overdose leads to mitochondrial dysfunction and the disruption of the mitochondrial respiratory chain [12]. Moreover, NAPQI inhibits both NADH (complex I)- and succinate (complex II)-driven

respiration in isolated mouse liver mitochondria or permeabilized mouse hepatocytes, apparently without affecting the complexes III and IV [76]. A decrease in the contribution of the bound form of NAD(P)H is also associated with a drop in the ATP content in hepatocytes, which has previously been reported [10,11]. In Figure 4b, a large standard deviation of a_2 in the MFC model was observed, which can be attributed to significant differences in the metabolic states of the hepatocytes isolated from tissue. In this state, hepatocytes have a varying baseline level of metabolic activity. In addition, this may be due to different individual sensitivity of cells to the toxin. Models where the tissue structure is conserved (ex vivo and slices) are better able to maintain cell homeostasis, and, therefore, the metabolic state is more stable.

In the slice model, there was a sharp increase in the value of the contribution of a_2 after 24 h of cultivation (3 h: $29.42\% \pm 3.5$, and 24 h: $33.66\% \pm 4.2$) (Figure 4). A similar trend was observed in the ex vivo model; there was a significant growth in the values of the a_2 contribution at 24 h after the introduction of APAP ($38.59\% \pm 3.6$) (Figure 4). Both in the slice model and in the animal model, the values of a_2 significantly increased compared to the control data (no added toxin). Thus, in the slices and ex vivo samples, the characteristic decrease in the intensity of OXPHOS that was observed in the MFC model, was not present. The low a_2 values in the case of the MFC model can be explained by the enhanced sensitivity of isolated hepatocytes to the toxins. This finding is in agreement with previous studies. For instance, it had been demonstrated that 24 h after the exposure of isolated hepatocytes to APAP, a more rapid decrease in the levels of ATP and GSH occurred, indicating a larger decrease in hepatocyte viability [77]. By contrast, it is assumed that, where the tissue structure is maintained (in the slices and ex vivo samples), when the action of APAP is stopped, the mechanisms of ATP resynthesis are activated, this also explaining their increase in the contribution of the bound form of NAD(P)H [77,78].

Based on the above results, we can conclude that the isolated hepatocytes in the in vitro model (in the MFC model) are more sensitive to the influence of the toxin (APAP). Correspondingly, the preserved tissue structure (of the slice and ex vivo models) allows a better maintenance of hepatocyte homeostasis and provides for compensatory processes when exposed to APAP.

3.4. Analysis of the Metabolic State of Normal Hepatocytes from Rats

The metabolic state of hepatocytes from rats was analyzed. As previously mentioned, three types of models (MFC, slices and ex vivo) were used. The fluorescence lifetimes (t_1 and t_2 , ps) of the free and bound forms of NAD(P)H were similar in all three models (Supplementary Materials, Figure S13). This result indicates the stability of the metabolic activity of the hepatocytes in all the tested models. Thus, isolated rat hepatocytes were shown to have a more stable metabolic state compared to the isolated mouse hepatocytes (which showed changed values of t_1 and t_2).

The in vitro MFC model with normal (untreated) rat hepatocytes showed a significant rise in the contribution of the bound form of NAD(P)H after 24 h of cultivation, compared with 3 h (3 h: $25.54\% \pm 4.1$, and 24 h: $33.65\% \pm 2.7$) (Figure 5). For both rats and mice, lower a_2 values for the MFC model were observed after 3 h, compared to 24 h. This result can be explained by the stabilization of the metabolic state of the hepatocytes within 24 h after isolation from the tissue. It is known that oxidative phosphorylation predominates in normal hepatocytes [79]. Thus, we can conclude that within 24 h there is a shift in the metabolic activity of the hepatocytes to the specific level. The slice model showed a slight decrease in the contribution of a_2 , but in general, the metabolic state of hepatocytes in this model was stable (3 h: $27.05\% \pm 4.4$, and 24 h: $25.33\% \pm 2.3$) (Figure 5). In the hepatocytes of the ex vivo samples, the contribution of a_2 was $25.2\% \pm 1.3$ (Figure 5). Thus, the metabolic state of the hepatocytes in all three models was similar after 24 h, following the initial temporary shift in metabolic state of hepatocytes in the MFCs.




Figure 5. Metabolic imaging of control rat hepatocytes for the MFC, slice and ex vivo models. (a) Combined images of the bright-field and autofluorescence of NAD(P)H (left row) with pseudocolored FLIM images of the NAD(P)H of the hepatocytes (central and right rows), field of view is $213 \times 213 \mu\text{m}$; (b) scatter plots reflecting the distribution of the values of the fluorescence lifetime contributions of the bound form of NAD(P)H. Here, t_m (ps) is the amplitude-weighted mean lifetime (tm); a_2 (%) is the relative contribution of the bound form of NAD(P)H; scale bar: $50 \mu\text{m}$.

3.5. Analysis of the Hepatotoxicity of Ethanol

Next, we studied metabolic changes in the hepatocytes cultured in MFCs, as well as in hepatocytes present in the slices and in ex vivo samples under exposure to ethanol. Modeling chronic liver injury under the influence of ethanol usually takes 4–12 weeks [25,26]. In our work, the induction of chronic ethanol hepatotoxicity was carried out for 12 weeks. Based on previous observations, the values of the fluorescence lifetimes of the free (t_1) and bound (t_2) forms of NAD(P)H in the MFC model and in the slices were similar. The values of t_1 and t_2 for the ex vivo samples were significantly higher in comparison with the other models (Supplementary Materials, Figure S13). It is known that t_2 is composed of the signal from the bound form of NADH and NADPH (the phosphorylated form of NADH). However, in most cases, the contribution of NADPH is negligible and can be neglected [80]. The standard values of t_2 in the cells ranged from 1500 to 2200 ps. The unchanged lifetimes of the bound form of NAD(P)H in the MFC and slice models indicated that NADPH is not involved in the hepatocyte metabolism (similar to the case of APAP hepatotoxicity). The possible reason for this is the reduced content of GSH, since in these models (MFC and slices), the possibilities of compensatory processes are reduced. As previously reported, chronic ethanol consumption selectively decreases the mitochondrial

GSH level, presumably because of the impaired uptake of GSH from the cytosol to the mitochondrial matrix [81].

However, in the case of the ex vivo samples, there was an increase in the values of t_2 indicating an increase in the emphasis on the processes associated with NADPH. Thus, the obtained data can be explained by the involvement of antioxidant defense processes with an increase in GSH synthesis under the influence of ethanol [63,82–84].

In the MFC model, it was shown that the contribution of a_2 was significantly lower after 24 h of rat hepatocyte cultivation compared to 3 h (3 h: $31.62\% \pm 1.8$; 24 h: $24.44\% \pm 4.9$) (Figure 6). In the microfluidic approach, the a_2 values after 24 h of culturing were lower than in the normal hepatocytes. In the animal model (ex vivo), the value of the contribution of a_2 after 12 weeks of induction of chronic pathology was $22.75\% \pm 2$ (Figure 6); this value is also lower than in the liver tissue of healthy animals.




Figure 6. Metabolic imaging of rat hepatocytes exposed to ethanol in the MFC, slice and ex vivo models. (a) Combined images of the bright-field and autofluorescence of NAD(P)H (left row) with pseudocolor-coded FLIM images of the NAD(P)H of the hepatocytes (central and right rows), field of view is $213 \times 213 \mu\text{m}$; (b) scatter plots reflecting the distribution of the values of the fluorescence lifetime contributions of the bound form of NAD(P)H. Here, t_m (ps) is the amplitude-weighted mean lifetime (tm); a_2 (%) is the relative contribution of the bound form of NAD(P)H; scale bar: $50 \mu\text{m}$.

The results obtained in the animal model and in the isolated hepatocytes are in good agreement with the previous studies. In the rat model after chronic ethanol exposure, a profound defect in mitochondrial metabolism was reported [81], resulting in depressed mitochondrial protein synthesis and the associated loss of complexes involved in the

mitochondrial electron transport chain [85–87]. These chronic ethanol-induced alterations can also lead to depressed respiratory capacity and impaired OXPHOS, which are critical in the development of alcoholic liver injury [88,89].

Several studies have demonstrated a decrease in ATP content when exposed to ethanol [90,91]. Indeed, mitochondria isolated from the liver of alcohol-fed animals contain lower amounts of respiratory chain components compared to the mitochondria of non-treated animals. In addition, it has been shown that animals exposed to alcohol had lower levels of the enzyme complex that mediates ATP production. As a result, the rate of ATP synthesis in such liver mitochondria is depressed as well, leading to an overall decline in ATP content in the hepatocytes [92]. Therefore, disruption of the mitochondrial respiratory chain leads to the decreased contribution of the bound form of NAD(P)H seen in the ex vivo models and in isolated hepatocytes.

By contrast, according to the data obtained, the metabolic state remained approximately constant between 3 h and 24 h (3 h: 25.18 ± 3.9 , and 24 h: 26.46 ± 2.9) in the slice model (Figure 6). The exposure to ethanol also disrupted the processes of glycolysis, additionally contributing to a decrease in the ATP content in the cells and to their further damage. However, compensatory processes often occur in liver cells at the early stages of ethanol exposure [90–92]. Thus, the stability of the a_2 value in the case of the slice model may be associated with a simultaneous decrease in two processes at once (glycolysis and OXPHOS) and compensatory processes occurring as a result of the slice model being more complex compared to the isolated cells, allowing the cells in the slices to maintain the balance of their metabolic state.

It can be concluded that the results obtained in the models of isolated hepatocytes and in the animal model are consistent with each other and reflect the known mechanisms of ethanol hepatotoxicity more accurately than do the slices. The exposure of slices to ethanol for 24 h is not enough to allow for the analysis of the metabolic changes that had been clearly observed in the slices in the APAP hepatotoxicity model. This is probably associated with the resistivity of the hepatocytes to the toxic effects of ethanol in the slice model due to the preservation of the native tissue structure [77,78].

4. Histological Analysis of Hepatocytes

Well-established histological alterations of hepatocytes after APAP administration include extensive centrilobular coagulative necrosis of the hepatocytes, the dilatation of sinusoids, and microvesicular and macrovesicular steatosis. The microvesicular steatosis occurs as a consequence of direct toxicity on the mitochondria and their oxidative processes. Macrovesicular steatosis corresponds to triglyceride accumulation due to defects in lipoprotein metabolism, damage to the plasma membrane, or to increased lipid delivery to the hepatocytes following an increased synthesis or mobilization [93]. In our case, histological analysis confirmed the presence of similar pathological changes associated with exposure to APAP, both in the slices and in the ex vivo samples obtained from animals. We observed severe fatty infiltration, dilatation of sinusoids and cell edema. However, the number of necrotic hepatocytes was insignificant (Figure 7).

Under exposure to ethanol, histological changes include coagulation necrosis of the hepatocytes, swollen hepatocytes, and cytoplasmic vacuolation (vesicular steatosis). With chronic exposure, serious alterations of the normal parenchyma architecture and fibrosis occur [94]. Here, we have also confirmed the presence of pathological changes associated with exposure to ethanol. In the slices, we revealed necrosis of the hepatocytes and a pronounced fatty infiltration of the cells. As the process of fibrosis is complex and systemic, its development cannot be observed in the slice model [95]. However, in the ex vivo model, in addition to fatty infiltration, we did observe initial signs of tissue fibrosis (Figure 8).




Figure 7. Histological images of liver tissue in the normal state and when exposed to APAP. Hematoxylin and eosin staining, $\times 400$; scale bar: 50 μm .




Figure 8. Histological images of liver tissue in its normal state and when exposed to ethanol. Hematoxylin and eosin staining, $\times 400$; scale bar: 50 μm .

Thus, toxic damage induced in liver tissue was confirmed for both toxins. The metabolic state of the hepatocytes in the MFC model corresponded to the known mechanisms of toxic damage, indicating the relevance and potential value of this model.

5. Conclusions

The comparative study on the hepatotoxicity of APAP and ethanol was performed using three models: MFCs, tissue slices, and an animal model (ex vivo samples). In the presence of APAP (mouse ex vivo model), we showed that conservation of the tissue structure (in the slices and ex vivo models) allows a better maintenance of the metabolic state of the hepatocytes and enables compensatory processes to occur, while in the MFC model, we revealed a characteristic decrease in the intensity of OXPPOS and an increased sensitivity of the isolated hepatocytes to the toxin. In the presence of ethanol (rat model), the values of t_1 and t_2 for the ex vivo samples were significantly higher in comparison to the other models, probably due to the higher contribution of NADPH, as a compensatory reaction. In the MFC and ex vivo models, we showed that the emphasis on OXPPOS was significantly reduced, which precisely reflects the known mechanisms of ethanol hepatotoxicity. At the same time, no significant changes in a_2 were revealed in the slice model; thus, the exposure of slices to ethanol for 24 h is apparently not enough to develop detectable metabolic changes in the hepatocytes. This was similar to the APAP hepatotoxicity model, where no metabolic changes were observed, either. In general, the changes in the metabolic state of isolated hepatocytes in the MFC model corresponded to the known mechanisms of hepatotoxicity of APAP and ethanol, and we assume that such MFCs can therefore be used as effective tools for express modeling of the hepatotoxicity of various agents. The FLIM technique, which was used to analyze the metabolic state of the hepatocytes, has demonstrated its efficacy for the express assessment of the effects of various toxic agents and can be further successfully translated into clinical settings.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/cells10112894/s1>, Supplementary Materials (presented in PDF) includes extended information on the using materials, fabrication of microfluidic chips, numerical simulation of flows in MFCs, MFCs experimental setup, animal modeling, precision cut liver slices preparation technique, multiphoton microscopy setup, FLIM data on fluorescence lifetimes values of NAD(P)H (t_1 and t_2 , ps), and histological analysis protocol.

Author Contributions: Conceptualization, E.Z., V.Z., M.Z. and D.K.; Investigation and methodology, S.R., V.E., M.K., I.K. and M.Z.; Writing—original draft, S.R.; Writing—review and editing, M.Z., A.T., I.K., V.E., E.Z. and D.K.; Supervision, E.Z. and D.K. All authors have read and agreed to the published version of the manuscript.

Funding: The work was supported by the Russian Science Foundation Grant №19-15-00263 (metabolic imaging and analysis of two-photon FLIM data of liver tissue), the Grant of the President of the Russian Federation MK-1649.2021.3 (morphological study), and the State task of performing an experimental development of Privolzhsky Research Medical University “Development of a test-system for determining individual drug sensitivity of patient tumors” (microfluidic chip development).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. The animals were kept in accordance with the rules adopted by the European Convention for the Protection of Vertebrate Animals (Strasbourg, 1986) and Principles on Good Laboratory Practice (OECD, ENV/MC/CUEM (98) 17, 1997). The local ethics committee at the Privolzhsky Research Medical University approved all animal procedures.

Informed Consent Statement: Not applicable.

Data Availability Statement: All relevant data are within the paper and its Supplementary Materials.

Acknowledgments: We thanks Marina V. Shirmanova, Irina N. Druzhkova and Nadezhda I. Ignatova for help in set-up the parameters of the microfluidic system.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ahmad, F.; Tabassum, N. Experimental models used for the study of antihepatotoxic agents. *J. Acute Dis.* **2012**, *1*, 85–89. [[CrossRef](#)]
2. Saito, C.; Zwingmann, C.; Jaeschke, H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. *Hepatology* **2010**, *51*, 246–254. [[CrossRef](#)]
3. O’Shea, R.S.; Dasarathy, S.; McCullough, A.J.; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. *Hepatology* **2010**, *51*, 307–328. [[CrossRef](#)]
4. Nguyen, N.T.; Du, K.; Akakpo, J.Y.; Umbaugh, D.S.; Jaeschke, H.; Ramachandran, A. Mitochondrial protein adduct and superoxide generation are prerequisites for early activation of c-jun N-terminal kinase within the cytosol after an acetaminophen overdose in mice. *Toxicol. Lett.* **2021**, *338*, 21–31. [[CrossRef](#)]
5. Mossanen, J.C.; Tacke, F. Acetaminophen-induced acute liver injury in mice. *Lab. Anim.* **2015**, *49*, 30–36. [[CrossRef](#)] [[PubMed](#)]
6. Lancaster, E.M.; Hiatt, J.R.; Zarrinpar, A. Acetaminophen hepatotoxicity: An updated review. *Arch. Toxicol.* **2015**, *89*, 193–199. [[CrossRef](#)]
7. Kalinec, G.M.; Thein, P.; Parsa, A.; Yorgason, J.; Luxford, W.; Urrutia, R.; Kalinec, F. Acetaminophen and NAPQI are toxic to auditory cells via oxidative and endoplasmic reticulum stress-dependent pathways. *Hear. Res.* **2014**, *313*, 26–37. [[CrossRef](#)] [[PubMed](#)]
8. Jiang, Y.; Fan, X.; Wang, Y.; Chen, P.; Zeng, H.; Tan, H.; Gonzalez, F.J.; Huang, M.; Bi, H. Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration. *Toxicol. Sci.* **2015**, *143*, 107–115. [[CrossRef](#)]
9. Jiang, Y.; Fan, X.; Wang, Y.; Tan, H.; Chen, P.; Zeng, H.; Huang, M.; Bi, H. Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation. *Chem.-Biol. Interact.* **2015**, *231*, 83–89. [[CrossRef](#)]
10. McGill, M.R.; Lebofsky, M.; Norris, H.R.; Slawson, M.H.; Bajt, M.L.; Xie, Y.; Williams, C.D.; Wilkins, D.G.; Rollins, D.E.; Jaeschke, H. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: Dose–response, mechanisms, and clinical implications. *Toxicol. Appl. Pharm.* **2013**, *269*, 240–249. [[CrossRef](#)]
11. Moyer, A.M.; Fridley, B.L.; Jenkins, G.D.; Batzler, A.J.; Pelleymounter, L.L.; Kalari, K.R.; Ji, Y.; Chai, Y.; Nordgren, K.K.; Weinsilboum, R.M. Acetaminophen-NAPQI hepatotoxicity: A cell line model system genome-wide association study. *Toxicol. Sci.* **2011**, *120*, 33–41. [[CrossRef](#)] [[PubMed](#)]
12. Heard, K.J. Acetylcysteine for acetaminophen poisoning. *N. Engl. J. Med.* **2008**, *359*, 285–922. [[CrossRef](#)]
13. Waring, W.S.; Stephen, A.F.; Malkowska, A.M.; Robinson, O.D. Acute ethanol coingestion confers a lower risk of hepatotoxicity after deliberate acetaminophen overdose. *Acad. Emerg. Med.* **2008**, *15*, 54–58. [[CrossRef](#)] [[PubMed](#)]
14. Gyamlani, G.G.; Parikh, C.R. Acetaminophen toxicity: Suicidal vs accidental. *Crit Care* **2002**, *6*, 1–5. [[CrossRef](#)]
15. Larson, A.M. Acetaminophen hepatotoxicity. *Clin. Liver Dis.* **2007**, *11*, 525–548. [[CrossRef](#)] [[PubMed](#)]
16. Cederbaum, A.I. Alcohol metabolism. *Clin. Liver Dis.* **2012**, *16*, 667–685. [[CrossRef](#)] [[PubMed](#)]
17. Yu, H.S.; Oyama, T.; Isse, T.; Kitagawa, K.; Tanaka, M.; Kawamoto, T. Formation of acetaldehyde-derived DNA adducts due to alcohol exposure. *Chem.-Biol. Interact.* **2010**, *188*, 367–375. [[CrossRef](#)]
18. Sun, Q.; Zhong, W.; Zhang, W.; Zhou, Z. Defect of mitochondrial respiratory chain is a mechanism of ROS overproduction in a rat model of alcoholic liver disease: Role of zinc deficiency. *Am. J. Physiol.* **2016**, *310*, G205–G214. [[CrossRef](#)]
19. Dou, X.; Shen, C.; Wang, Z.; Li, S.; Zhang, X.; Song, Z. Protection of nicotinic acid against oxidative stress-induced cell death in hepatocytes contributes to its beneficial effect on alcohol-induced liver injury in mice. *J. Nutr. Biochem.* **2013**, *24*, 1520–1528. [[CrossRef](#)]
20. Song, Z.; Zhou, Z.; Chen, T.; Hill, D.; Kang, J.; Barve, S.; McClain, C. S-adenosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice. *J. Nutr. Biochem.* **2003**, *14*, 591–597. [[CrossRef](#)]
21. Bao, W.; Li, K.; Rong, S.; Yao, P.; Hao, L.; Ying, C.; Zhang, X.; Nussler, A.; Liu, L. Curcumin alleviates ethanol-induced hepatocytes oxidative damage involving heme oxygenase-1 induction. *J. Ethnopharmacol.* **2010**, *128*, 549–553. [[CrossRef](#)] [[PubMed](#)]
22. Ramachandran, A.; Lebofsky, M.; Baines, C.P.; Lemasters, J.J.; Jaeschke, H. Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury. *Free Radic. Res.* **2011**, *45*, 156–164. [[CrossRef](#)] [[PubMed](#)]
23. Kucera, O.; Cervinkova, Z. Experimental models of non-alcoholic fatty liver disease in rats. *World J. Gastroenterol.* **2014**, *20*, 8364. [[CrossRef](#)] [[PubMed](#)]
24. Trevisiol, C.H.; Turner, R.T.; Pfaff, J.E.; Hunter, J.C.; Menagh, P.J.; Hardin, K.; Ho, E.; Iwaniec, U.T. Impaired osteoinduction in a rat model for chronic alcohol abuse. *Bone* **2007**, *41*, 175–180. [[CrossRef](#)]
25. Lamas-Paz, A.; Hao, F.; Nelson, L.J.; Vázquez, M.T.; Canals, S.; Del Moral, M.G.; Martínez-Naves, E.; Nevzorova, Y.A.; Cubero, F.J. Alcoholic liver disease: Utility of animal models. *World J. Gastroenterol.* **2018**, *24*, 5063. [[CrossRef](#)] [[PubMed](#)]
26. Antushevich, A.E.; Grebenyuk, A.N.; Khalyutin, D.A.; Yartseva, A.A. Experimental modeling of alcohol-induced liver cirrhosis in rats. *Bull. Exp. Biol. Med.* **2018**, *164*, 404–407. [[CrossRef](#)]
27. Prins, G.H.; Luangmonkong, T.; Oosterhuis, D.; Mutsaers, H.A.; Dekker, F.J.; Olinga, P. A pathophysiological model of non-alcoholic fatty liver disease using precision-cut liver slices. *Nutrients* **2019**, *11*, 507. [[CrossRef](#)] [[PubMed](#)]
28. Palma, E.; Doornebal, E.J.; Chokshi, S. Precision-cut liver slices: A versatile tool to advance liver research. *Hepatol. Int.* **2019**, *13*, 51–57. [[CrossRef](#)]
29. Groneberg, D.A.; Grosse-Siestrup, C.; Fischer, A. In vitro models to study hepatotoxicity. *Toxicol. Pathol.* **2002**, *30*, 394–399. [[CrossRef](#)] [[PubMed](#)]

30. Cong, Y.; Han, X.; Wang, Y.; Chen, Z.; Lu, Y.; Liu, T.; Wu, Z.; Jin, Y.; Luo, Y.; Zhang, X. Drug Toxicity Evaluation Based on Organ-on-a-Chip Technology: A Review. *Micromachines* **2020**, *11*, 381. [[CrossRef](#)]
31. Toh, Y.C.; Lim, T.C.; Tai, D.; Xiao, G.; van Noort, D.; Yu, H. A microfluidic 3D hepatocyte chip for drug toxicity testing. *Lab Chip* **2009**, *9*, 2026–2035. [[CrossRef](#)]
32. De Ninno, A.; Bertani, F.R.; Gerardino, A.; Schiavoni, G.; Musella, M.; Galassi, C.; Mattei, F.; Sistigu, A.; Businaro, L. Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments. *J. Vis. Exp.* **2021**. [[CrossRef](#)]
33. Wang, L.; Li, X.; Chen, C. Inhibition of acetaminophen-induced hepatotoxicity in mice by exogenous thymosin β 4 treatment. *Int. Immunopharmacol.* **2018**, *61*, 20–28. [[CrossRef](#)] [[PubMed](#)]
34. Zhu, L.; Huang, X.; Li, Z.; Cao, G.; Zhu, X.; She, S.; Huang, T.; Lu, G. Evaluation of hepatotoxicity induced by 2-ethylhexyldiphenyl phosphate based on transcriptomics and its potential metabolism pathway in human hepatocytes. *J. Hazard. Mater.* **2021**, *413*, 125281. [[CrossRef](#)] [[PubMed](#)]
35. Muldrew, K.L.; James, L.P.; Coop, L.; McCullough, S.S.; Hendrickson, H.P.; Hinson, J.A.; Mayeux, P.R. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. *Drug Metab. Dispos.* **2002**, *30*, 446–451. [[CrossRef](#)] [[PubMed](#)]
36. Roberts, M.S.; Dancik, Y.; Prow, T.W.; Thorling, C.A.; Lin, L.L.; Grice, J.E.; Robertson, T.A.; König, K.; Becker, W. Non-invasive imaging of skin physiology and percutaneous penetration using fluorescence spectral and lifetime imaging with multiphoton and confocal microscopy. *Eur. J. Pharm. Biopharm.* **2011**, *77*, 469–488. [[CrossRef](#)] [[PubMed](#)]
37. Bird, D.K.; Yan, L.; Vrotsos, K.M.; Eliceiri, K.W.; Vaughan, E.M.; Keely, P.J.; White, J.G.; Ramanujam, N. Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. *Cancer Res.* **2005**, *65*, 8766–8773. [[CrossRef](#)]
38. Lakner, P.H.; Monaghan, M.G.; Möller, Y.; Olayioye, M.A.; Schenke-Layland, K. Applying phasor approach analysis of multiphoton FLIM measurements to probe the metabolic activity of three-dimensional in vitro cell culture models. *Sci. Rep.* **2017**, *7*, 42730. [[CrossRef](#)]
39. Wang, H.; Liang, X.; Gravot, G.; Thorling, C.A.; Crawford, D.H.; Xu, Z.P.; Liu, X.; Roberts, M.S. Visualizing liver anatomy, physiology and pharmacology using multiphoton microscopy. *J. Biophotonics* **2017**, *10*, 46–60. [[CrossRef](#)]
40. Sun, Y.; Phipps, J.; Elson, D.S.; Stoy, H.; Tinling, S.; Meier, J.; Poirier, B.; Chuang, F.S.; Farwell, D.G.; Marcu, L. Fluorescence lifetime imaging microscopy: In vivo application to diagnosis of oral carcinoma. *Opt. Lett.* **2009**, *34*, 2081–2083. [[CrossRef](#)]
41. Sun, Y.; Phipps, J.E.; Meier, J.; Hatami, N.; Poirier, B.; Elson, D.S.; Farwell, D.G.; Marcu, L. Endoscopic fluorescence lifetime imaging for in vivo intraoperative diagnosis of oral carcinoma. *Microsc. Microanal.* **2013**, *19*, 791–798. [[CrossRef](#)]
42. Liang, X.; Wang, H.; Liu, X.; Roberts, M. Quantitative optical imaging of paracetamol-induced metabolism changes in the liver. In *SPIE BioPhotonics Australasia (10013)*; International Society for Optics and Photonics: Adelaide, Australia, 2016; p. 100131H.
43. Roberts, M.S.; Barkauskas, D.S.; Wang, H.; Liu, X.; Studier, H.; Pastore, M.N.; Zhang, R.; Holmes, A.; Grice, J.E.; Xu, Z.; et al. Multiphoton and FLIM imaging in quantifying ex vivo and in vivo body organ kinetics of solutes. In *Multiphoton Microscopy in the Biomedical Sciences XX (11244)*; International Society for Optics and Photonics: Bellingham, WA, USA, 2020; p. 112440S.
44. Becker, W. Fluorescence lifetime imaging—techniques and applications. *J. Microsc.* **2012**, *247*, 119–136. [[CrossRef](#)]
45. Berezin, M.Y.; Achilefu, S. Fluorescence lifetime measurements and biological imaging. *Chem. Rev.* **2010**, *110*, 2641–2684. [[CrossRef](#)] [[PubMed](#)]
46. Skala, M.C.; Richtig, K.M.; Gendron-Fitzpatrick, A.; Eickhoff, J.; Eliceiri, K.W.; White, J.G.; Ramanujam, N. In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 19494–19499. [[CrossRef](#)] [[PubMed](#)]
47. Chorvat, D.; Chorvatova, A. Multi-wavelength fluorescence lifetime spectroscopy: A new approach to the study of endogenous fluorescence in living cells and tissues. *Laser Phys. Lett.* **2009**, *6*, 175–193. [[CrossRef](#)]
48. Van Manen, H.J.; Verkuiljen, P.; Wittendorp, P.; Subramaniam, V.; Van den Berg, T.K.; Roos, D.; Otto, C. Refractive index sensing of green fluorescent proteins in living cells using fluorescence lifetime imaging microscopy. *Biophys. J.* **2008**, *94*, 67–69. [[CrossRef](#)] [[PubMed](#)]
49. Lakowicz, J.R.; Szmajcinski, H.; Nowaczyk, K.; Johnson, M.L. Fluorescence lifetime imaging of free and protein-bound NADH. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 1271–1275. [[CrossRef](#)] [[PubMed](#)]
50. Wang, H.; Liang, X.; Mohammed, Y.H.; Thomas, J.A.; Bridle, K.R.; Thorling, C.A.; Grice, J.E.; Xu, Z.P.; Liu, X.; Crawford, D.H.; et al. Real-time histology in liver disease using multiphoton microscopy with fluorescence lifetime imaging. *Biomed. Opt. Express* **2015**, *6*, 780–792. [[CrossRef](#)] [[PubMed](#)]
51. Thorling, C.A.; Jin, L.; Weiss, M.; Crawford, D.; Liu, X.; Burczynski, F.J.; Liu, D.; Wang, H.; Roberts, M.S. Assessing steatotic liver function after ischemia-reperfusion injury by in vivo multiphoton imaging of fluorescein disposition. *Biopharm. Drug Dispos.* **2015**, *43*, 154–162. [[CrossRef](#)] [[PubMed](#)]
52. Thorling, C.A.; Crawford, D.; Burczynski, F.J.; Liu, X.; Liao, I.; Roberts, M.S. Multiphoton microscopy in defining liver function. *J. Biomed. Opt.* **2014**, *19*, 090901. [[CrossRef](#)]
53. Rodimova, S.A.; Kuznetsova, D.S.; Bobrov, N.V.; Gulina, A.A.; Reunov, D.G.; Karabut, M.M.; Shcheslavskiy, V.I.; Vdovina, N.V.; Zagaynov, V.E.; Zagaynova, E.V. Interrogation of the Liver During Regeneration by Fluorescence Lifetime Imaging and Mass Spectrometry. *IEEE J. Sel. Top. Quantum Electron.* **2021**, *27*, 1–11. [[CrossRef](#)]
54. Kuznetsova, D.S.; Rodimova, S.A.; Gulina, A.; Reunov, D.; Bobrov, N.; Polozova, A.V.; Vasin, A.; Shcheslavskiy, V.I.; Vdovina, N.; Zagaynov, V.E.; et al. Metabolic imaging and secondary ion mass spectrometry to define the structure and function of liver with acute and chronic pathology. *J. Biomed. Opt.* **2019**, *25*, 014508. [[CrossRef](#)] [[PubMed](#)]

55. Rui, L. Energy metabolism in the liver. *Compr. Physiol.* **2011**, *4*, 177–197.
56. Chaban, Y.; Boekema, E.J.; Dudkina, N.V. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilization. *Biochim. Biophys. Acta* **2014**, *1837*, 418–426. [[CrossRef](#)] [[PubMed](#)]
57. Smeitink, J.; van den Heuvel, L.; DiMauro, S. The genetics and pathology of oxidative phosphorylation. *Nat. Rev. Genet.* **2001**, *2*, 342–352. [[CrossRef](#)] [[PubMed](#)]
58. Cairns, R.A.; Harris, I.S.; Mak, T.W. Regulation of cancer cell metabolism. *Nat. Rev. Cancer* **2011**, *11*, 85–95. [[CrossRef](#)] [[PubMed](#)]
59. Luengo, A.; Li, Z.; Gui, D.Y.; Sullivan, L.B.; Zagorulya, M.; Do, B.T.; Ferreira, R.; Naamati, A.; Ali, A.; Lewis, C.A.; et al. Increased demand for NAD⁺ relative to ATP drives aerobic glycolysis. *Mol. Cell* **2021**, *81*, 691–707. [[CrossRef](#)] [[PubMed](#)]
60. Chan, T.S.; Cassim, S.; Raymond, V.A.; Gottschalk, S.; Merlen, G.; Zwingmann, C.; Lapierre, P.; Darby, P.; Mazer, C.D.; Bilodeau, M. Upregulation of Krebs cycle and anaerobic glycolysis activity early after onset of liver ischemia. *PLoS ONE* **2018**, *13*, e0199177. [[CrossRef](#)]
61. Nsiah-Sefaa, A.; McKenzie, M. Combined defects in oxidative phosphorylation and fatty acid β -oxidation in mitochondrial disease. *BioSci. Rep.* **2016**, *36*, e00313. [[CrossRef](#)]
62. Li, W.C.; Ralphs, K.L.; Tosh, D. Isolation and culture of adult mouse hepatocytes. In *Mouse Cell Culture*; Humana Press: Luxembourg, 2010; pp. 185–196. [[CrossRef](#)]
63. Hall, P.D.; Lieber, C.S.; DeCarli, L.M.; French, S.W.; Lindros, K.O.; Järveläinen, H.; Bode, C.; Parlesak, A.; Bode, J.C. Models of alcoholic liver disease in rodents: A critical evaluation. *Alcohol. Clin. Exp. Res.* **2001**, *25*, 254S–261S. [[CrossRef](#)]
64. Jaeschke, H.; McGill, M.R.; Williams, C.D.; Ramachandran, A. Current issues with acetaminophen hepatotoxicity—a clinically relevant model to test the efficacy of natural products. *Life Sci.* **2011**, *88*, 737–745. [[CrossRef](#)] [[PubMed](#)]
65. Van Midwoud, P.M.; Groothuis, G.M.; Merema, M.T.; Verpoorte, E. Microfluidic biochip for the perfusion of precision-cut rat liver slices for metabolism and toxicology studies. *Biotechnol. Bioeng.* **2010**, *105*, 184–194. [[CrossRef](#)] [[PubMed](#)]
66. Chen, L.C.; Lloyd, W.R.; Kuo, S.; Kim, H.M.; Marcelo, C.L.; Feinberg, S.E.; Mycek, M.A. The potential of label-free nonlinear optical molecular microscopy to non-invasively characterize the viability of engineered human tissue constructs. *Biomaterials* **2014**, *35*, 6667–6676. [[CrossRef](#)]
67. Kolenc, O.I.; Quinn, K.P. Evaluating cell metabolism through autofluorescence imaging of NAD(P)H and FAD. *Antioxid. Redox Signal.* **2019**, *30*, 875–889. [[CrossRef](#)]
68. Meleshina, A.V.; Dudenkova, V.V.; Bystrova, A.S.; Kuznetsova, D.S.; Shirmanova, M.V.; Zagaynova, E.V. Two-photon FLIM of NAD(P)H and FAD in mesenchymal stem cells undergoing either osteogenic or chondrogenic differentiation. *Stem Cell Res.* **2017**, *8*, 1–10. [[CrossRef](#)] [[PubMed](#)]
69. Vorrink, S.U.; Zhou, Y.; Ingelman-Sundberg, M.; Lauschke, V.M. Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions. *Toxicol. Sci.* **2018**, *163*, 655–665. [[CrossRef](#)] [[PubMed](#)]
70. Chakraborty, S.; Nian, F.S.; Tsai, J.W.; Karmenyan, A.; Chiou, A. Quantification of the metabolic state in cell-model of Parkinson’s disease by fluorescence lifetime imaging microscopy. *Sci. Rep.* **2016**, *6*, 1–9. [[CrossRef](#)] [[PubMed](#)]
71. Lukina, M.M.; Shimolina, L.E.; Kiselev, N.M.; Zagaynov, V.E.; Komarov, D.V.; Zagaynova, E.V.; Shirmanova, M.V. Interrogation of tumor metabolism in tissue samples ex vivo using fluorescence lifetime imaging of NAD(P)H. *Methods Appl. Fluoresc.* **2019**, *8*, 014002. [[CrossRef](#)]
72. Yang, S.; Tan, T.M.C.; Wee, A.; Leow, C.K. Mitochondrial respiratory function and antioxidant capacity in normal and cirrhotic livers following partial hepatectomy. *Cell Mol. Life Sci.* **2004**, *61*, 220–229. [[CrossRef](#)]
73. Liu, C.; Sekine, S.; Ito, K. Assessment of mitochondrial dysfunction-related, drug-induced hepatotoxicity in primary rat hepatocytes. *Toxicol. Appl. Pharm.* **2016**, *302*, 23–30. [[CrossRef](#)] [[PubMed](#)]
74. Ito, Y.; Bethea, N.W.; Abril, E.R.; McCuskey, R.S. Early hepatic microvascular injury in response to acetaminophen toxicity. *Microcirculation* **2003**, *10*, 391–400. [[CrossRef](#)] [[PubMed](#)]
75. Ruepp, S.U.; Tonge, R.P.; Shaw, J.; Wallis, N.; Pognan, F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. *Toxicol. Sci.* **2002**, *65*, 135–150. [[CrossRef](#)]
76. Lee, K.K.; Imaizumi, N.; Chamberland, S.R.; Alder, N.N.; Boelsterli, U.A. Targeting mitochondria with methylene blue protects mice against acetaminophen-induced liver injury. *Hepatology* **2015**, *61*, 326–336. [[CrossRef](#)]
77. George, E.; Murdock, J.; Aylott, M.; Westmoreland, C. Comparison of hepatocyte cultures and liver slices in in vitro toxicity testing. *Altern. Lab. Anim.* **1999**, *27*, 769–781. [[CrossRef](#)]
78. Granitzny, A.; Knebel, J.; Schaudien, D.; Braun, A.; Steinberg, P.; Dasenbrock, C.; Hansen, T. Maintenance of high quality rat precision cut liver slices during culture to study hepatotoxic responses: Acetaminophen as a model compound. *Toxicol. Vitro.* **2017**, *42*, 200–213. [[CrossRef](#)] [[PubMed](#)]
79. Lee, N.C.; Carella, M.A.; Papa, S.; Bubici, C. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer. *Front. Cell Dev. Biol.* **2018**, *6*, 138. [[CrossRef](#)] [[PubMed](#)]
80. Blacker, T.S.; Mann, Z.F.; Gale, J.E.; Ziegler, M.; Bain, A.J.; Szabadkai, G.; Duchon, M.R. Separating NADH and NADPH fluorescence in live cells and tissues using FLIM. *Nat. Commun.* **2014**, *5*, 1–9. [[CrossRef](#)] [[PubMed](#)]
81. Venkatraman, A.; Shiva, S.; Wigley, A.; Ulasova, E.; Chhieng, D.; Bailey, S.M.; Darley-Usmar, V.M. The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. *Hepatology* **2004**, *40*, 565–573. [[CrossRef](#)] [[PubMed](#)]
82. Vishwasrao, H.D.; Heikal, A.A.; Kasischke, K.A.; Webb, W.W. Conformational dependence of intracellular NADH on metabolic state revealed by associated fluorescence anisotropy. *J. Biol. Chem.* **2005**, *280*, 25119–25126. [[CrossRef](#)]

83. Atashi, F.; Modarressi, A.; Pepper, M.S. The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: A review. *Stem Cells Dev.* **2015**, *24*, 1150–1163. [[CrossRef](#)] [[PubMed](#)]
84. Couto, N.; Wood, J.; Barber, J. The role of glutathione reductase and related enzymes on cellular redox homeostasis network. *Free Radic. Biol. Med.* **2016**, *95*, 27–42. [[CrossRef](#)] [[PubMed](#)]
85. Bailey, S.M.; Robinson, G.; Pinner, A.; Chamlee, L.; Ulasova, E.; Pompilius, M. S-adenosylmethionine prevents chronic alcohol-induced mitochondrial dysfunction in the rat liver. *Am. J. Physiol.* **2006**, *291*, G857–G867. [[CrossRef](#)] [[PubMed](#)]
86. Sykora, P.; Kharbanda, K.K.; Crumm, S.E.; Cahill, A. S-adenosyl-L-methionine co-administration prevents the ethanol-elicited dissociation of hepatic mitochondrial ribosomes in male rats. *Alcohol. Clin. Exp. Res.* **2009**, *33*, 1–9. [[CrossRef](#)] [[PubMed](#)]
87. Yan, M.; Zhu, P.; Liu, H.M.; Zhang, H.T.; Liu, L. Ethanol induced mitochondria injury and permeability transition pore opening: Role of mitochondria in alcoholic liver disease. *World J. Gastroenterol.* **2007**, *13*, 2352–2356. [[CrossRef](#)] [[PubMed](#)]
88. Kharbanda, K.K.; Todero, S.L.; King, A.L.; Osna, N.A.; McVicker, B.L.; Tuma, D.J.; Wisecarver, J.L.; Bailey, S.M. Betaine treatment attenuates chronic ethanol-induced hepatic steatosis and alterations to the mitochondrial respiratory chain proteome. *Int. J. Hepatol.* **2012**, *2012*, 962183. [[CrossRef](#)]
89. Nassir, F.; Ibdah, J.A. Role of mitochondria in alcoholic liver disease. *World J. Gastroenterol.* **2014**, *20*, 2136. [[CrossRef](#)] [[PubMed](#)]
90. Young, T.A.; Bailey, S.M.; Van Horn, C.G.; Cunningham, C.C. Chronic ethanol consumption decreases mitochondrial and glycolytic production of ATP in liver. *Alcohol Alcohol.* **2006**, *41*, 254–260. [[CrossRef](#)] [[PubMed](#)]
91. Labonne, B.E.; Gutiérrez, M.; Gómez-Quiroz, L.E.; Fainstein, M.K.; Bucio, L.; Souza, V.; Flores, O.; Ortíz, V.; Hernández, E.; Kershenovich, D.; et al. Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage. *Cell Biol. Toxicol.* **2009**, *25*, 599. [[CrossRef](#)] [[PubMed](#)]
92. Cunningham, C.C. Energy availability and alcohol-related liver pathology. *Alcohol Res. Health* **2003**, *27*, 291. [[PubMed](#)]
93. Shahid, M.; Subhan, F. Comparative histopathology of acetaminophen induced hepatotoxicity in animal models of mice and rats. *Pharm. Online* **2014**, *3*, 32–43.
94. Turan, A.; Celik, I. Antioxidant and hepatoprotective properties of dried fig against oxidative stress and hepatotoxicity in rats. *Int. J. Biol. Macromol.* **2016**, *91*, 554–559. [[CrossRef](#)] [[PubMed](#)]
95. Trautwein, C.; Friedman, S.L.; Schuppan, D.; Pinzani, M. Hepatic fibrosis: Concept to treatment. *J. Hepatol.* **2015**, *62*, S15–S24. [[CrossRef](#)] [[PubMed](#)]